Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H33NO4 |
Molecular Weight | 411.5338 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@@](C)(O)[C@H]1C[C@@]23C=C[C@]1(OC)[C@@H]4OC5=C(O)C=CC6=C5[C@]24CCN(C)[C@@H]3C6
InChI
InChIKey=CAHCBJPUTCKATP-FAWZKKEFSA-N
InChI=1S/C25H33NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,9-10,17-18,21,27-28H,5,8,11-14H2,1-4H3/t17-,18-,21-,22-,23-,24+,25-/m1/s1
Molecular Formula | C25H33NO4 |
Molecular Weight | 411.5338 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Etorphine was the first potent opiate agonist employed primarily for use in non-domestic and wild species. Etorphine was 500 times as potent as morphine, with a very rapid onset and short duration of action. In morphine-dependent subjects, etorphine suppressed abstinence but for a shorter period than morphine. Etorphine is a full opiate agonist and binds to multiple opiate sites in the central nervous system. It is believed to produce its clinical effects through binding the µ-, δ-, and κ- opiate sites. It has a potent effect on depressing the respiratory centers of the CNS thus resulting in apnea being commonly seen in immobilized animals. Etorphine revolutionized the ability of biologists and veterinarians to safely capture and restrain many species that previously could not be handled. Etorphine is not currently commercially available due to lack of production by the manufacturer.
CNS Activity
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:44:19 GMT 2025
by
admin
on
Mon Mar 31 18:44:19 GMT 2025
|
Record UNII |
42M2Y6NU9O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN02AE90
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
||
|
DEA NO. |
9056
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D005048
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
644209
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
14521-96-1
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
4912
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
7601
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
SUB07339MIG
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
100000082092
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
DTXSID40878669
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
238-535-9
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
m5201
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | Merck Index | ||
|
42M2Y6NU9O
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
ETORPHINE
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
C80578
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL1908334
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
DB01497
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY | |||
|
2288
Created by
admin on Mon Mar 31 18:44:19 GMT 2025 , Edited by admin on Mon Mar 31 18:44:19 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
DPDPE-Cl binding to guinea pig brain membranes
Ki
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
TARGET -> AGONIST |
3H-DAMGO specific binding to gerbil ccrebellar membranes.
Ki
|
||
|
TARGET -> AGONIST |
3H-U-69593 binding to human placental P3
fraction.
Ki
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
7,8-dihydro-7α-[1-(R)-hydroxy-1-methylbutyl]-6,14-endoethanotetrahydrooripavine
(derivative of etorphine) as per INCB
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Semi-synthetic opioid possessing an analgesic potency approximately 1,000–3,000 times that of morphine
|